Galderma Must Pay Oracea Fees To NYU During Appeal

Law360, New York (April 18, 2013, 2:16 PM EDT) -- A New York federal judge ruled Wednesday that Galderma Laboratories Inc. will have to keep paying royalties to New York University for the patents behind rosacea treatment Oracea while the school appeals a decision that found the patents invalid.

Galderma wanted to stop paying licensing fees for Oracea after a federal judge ruled last year that NYU's patents weren't valid, but the school said the licensing contract required payments until the patents were declared invalid by a court “from which no appeal can be taken.”...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.